

Alexandre SOSTELLY¹, Léa PAYEN², Benjamin RIBBA³, Attilio DI PIETRO⁴, Pierre FALSON⁴,
Ahcene BOUMENDJEL⁵, Pascal GIRARD^{1,6}, Michel TOD^{1,7}

¹ EA3738 Ciblage Thérapeutique en Oncologie, Faculté de Médecine Lyon-Sud, Lyon; ² Institut des Sciences Pharmaceutiques et Biologiques, Lyon
³ INRIA Rhône Alpes, Project Team NUMED, Ecole Normale Supérieure de Lyon, Lyon; ⁴ Institut de Biologie et Chimie des Protéines, Lyon
⁵ Département de Pharmacochimie Moléculaire, Université Joseph FOURIER, Grenoble; ⁶ INSERM; ⁷ Hospices Civils de Lyon, Lyon

Introduction

- ATP Binding Cassette (ABC) transporters play an important role in anticancer drug resistance.
- Breast Cancer Resistance Protein (BCRP) is an ABC transporter involved in the efflux of a wide range of substrates such as Irinotecan (CPT-11) and its active metabolite SN38. BCRP is thus involved in CPT-11 resistance.
- MBLI87, a new BCRP inhibitor, has shown high activity against BCRP efflux in *in vitro* studies¹ and also against CPT-11 BCRP mediated resistance in xenografted mice².

Objectives

To model the interaction between BCRP inhibitors and CPT-11 in SCID mice with CPT-11 resistant xenografts
To compare MBLI87 effects with the BCRP reference inhibitor, gefitinib against CPT-11 BCRP mediated resistance

Data

- 60 SCID mice were inoculated with CPT-11 resistant or non resistant tumour cells at each flank
- Mice received drugs during a 2-week period followed by a 2-week rest period during 8 weeks
- 6 treatment arms : Control, CPT-11, Gefitinib, MBLI87 CPT-11+Gefitinib, CPT-11+MBLI87
- Tumour measurements (length and width) were assessed every 2 days after the 1st drug administration
- Geometric mean of the 4 measures (length, width on each flank) was calculated for each measure

—————> Geometric mean : Dependent Variable

Methods

- 2 families of model were tested :
 - Interaction models (Minto³, Greco⁴)
 - Tumour growth inhibition (TGI) models (Claret⁵, Simeoni⁶)
- Some modifications were added to the TGI models :
 - A K-PD⁷ model was used to describing drug kinetics
Drug effects were dependant on the amount of drugs
 - An interaction parameter was added to quantify the action of BCRP inhibitors on CPT-11 cytotoxic effect
- Model parameters were estimated by the FOCE method (NonMem VI)

Results

Interaction models

- Only one dose level is tested : Not possible to describe surface response as proposed by Minto
- Greco approach did not allow to describe properly tumour growth
—————> “Interaction models” were rejected

Tumour growth inhibition models

- Simeoni was preferred to the Claret model based on OFV and AIC values
 - Simeoni model : AIC = -453.0
 - Claret model : AIC = -440.2
- Final model is a modified Gompertz tumour growth inhibition model with K-PD and interaction components :
 - CPT-11 effect is related to the amount of drug in the kinetic compartment
 - BCRP inhibitors modifies CPT-11 activity

Final Model Equations

$$\frac{dA_x}{dt} = -K_{e,x} * A_x$$

$$\frac{d\phi_{tumour}}{dt} = \frac{\lambda_0 * \phi_{tumour}}{(1 + (\frac{\lambda_0}{\lambda_1} * \phi_{tumour})^\Psi)^{\frac{1}{\Psi}}} - K_{2,x} * DR_x * \phi_{tumour}$$

$$DR_x = K_{e,x} * A_x \qquad X: \text{CPT-11, gefitinib, MBLI87}$$

In case of joint administration, K2 parameter accounts for the effect of MBLI87 and gefitinib on CPT-11 cytotoxic effect

$$K_{2,CPT-11} = K' + K'' * DR_{Inhibitors} \qquad Inhibitors: \text{gefitinib, MBLI87}$$

A : Drug amount with a constant elimination rate K_e

λ_0, λ_1 : Gompertz parameters describing tumour growth

Ψ : Exponential to linear phase switch parameter

K_2 : Drug potency parameter

K'' : Interaction parameter

Final Model Evaluation




Figure 1: Population Predictions Individual Predictions, Observations vs Time
Blue lines: Observations, Predictions Red lines: Trend line

Individual Predictions plot show good model performances

Parameter Estimates

Parameter	Typical Value	%IIV
λ_0 (d ⁻¹)	0.06	33
λ_1 (mm.d ⁻¹)	0.2	46
$K_{2,CPT-11}$ (mg ⁻¹)	0.3	-
$K_{2,Gefitinib}$ (mg ⁻¹)	10 ⁻²	-
$K_{2,MBLI87}$ (mg ⁻¹)	10 ⁻²	-
$K''_{CPT-11,Gefitinib}$	10 ⁻²	-
$K''_{CPT-11,MBLI87}$	5.3	-

Table 1: Parameter Estimates

- Potency of BCRP inhibitors are estimated at 10⁻² mg⁻¹
—————> BCRP inhibitors alone have no effect
- A significant synergistic effect is found between MBLI87 and CPT-11 ($K''=5.3$)
- None is found with gefitinib ($K''=10^{-2}$)
- There is no difference in tumour size kinetics between these both cohorts, model confirms that interaction is stronger between MBLI87 and CPT-11

Conclusion

- Results show that MBLI87 is able to revert CPT-11 resistance at a 20-fold lower dose compared to gefitinib
- Future use of the model will be optimizing a dose finding study in mice

References:

1. Boumendjel A *et al.* BioOrg Med Chem 2007

2. Arnaud O *et al.* J Cell Mol Med Submitted

3. Minto *et al.* Anesthesiology 2000

4. Greco *et al.* Pharmacol Rev 1995

5. Claret *et al.* J Clin Oncol 2009

6. Simeoni *et al.* Can Res 2004

7. Jacqmin *et al.* J Pharmacokinet Pharmacodyn 2007